Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial.
Details
Serval ID
serval:BIB_8D842BC598BF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial.
Journal
Stroke
Working group(s)
Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack Vascular Ultrasound Study Investigators
Contributor(s)
Prevention of Cerebrovascular, Hennerici MG., Bots ML., Ford I., Laurent S., Touboul PJ., Anderson C., Donnan G., Phan T., Thijs V., Selchen D., Spence D., Bar M., Kanovsky P., Rektor I., Skoda O., Vaclavik D., Lucas C., Rosolacci T., Trouillas P., Griewing B., Hennerici M., Hetzel A., Koehler W., Roether J., Kaps M., Csanyi A., Csiba L., Kaposzta Z., Nikl J., Panczel G., Pongracz E., Szegedi N., Valikovics A., Cappelletti C., Di Piero V., Prati P., Rossini P., Bots ML., Kappelle LJ., Czlonkowska A., Kozubski W., Kuczynska-Zardzewialy A., Kwiecinsky H., Salgado AV., Butko D., Gusev E., Kamchatnov P., Kotov S., Parfenov V., Skvortsova V., Stakhovskaya L., Zvan B., Alvarez Sabin J., Castillo Sanchez J., Jimenez Martinez D., Serena Leal J., Trejo Gabriel JM. , Vivancos Mora J., Baumgartner RW., Hirt L., Lees K., MacWalter R.
ISSN
1524-4628 (Electronic)
ISSN-L
0039-2499
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
45
Number
8
Pages
2348-2353
Language
english
Abstract
BACKGROUND AND PURPOSE: Thromboxane prostaglandin receptors have been implicated to be involved in the atherosclerotic process. We assessed whether Terutroban, a thromboxane prostaglandin receptor antagonist, affects the progression of atherosclerosis, as measured by common carotid intima-media thickness and carotid plaques.
METHODS: A substudy was performed among 1141 participants of the aspirin-controlled Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) trial. Common carotid intima-media thickness and carotid plaque occurrence was measured during a 3-year period.
RESULTS: Baseline characteristics did not differ between Terutroban (n=592) and aspirin (n=549) treated patients and were similar as in the main study. Mean study and treatment duration were similar (28 and 25 months, respectively). In the Terutroban group, the annualized rate of change in common carotid intima-media thickness was 0.006 mm per year (95% confidence interval, -0.004 to 0.016) and -0.005 mm per year (95% confidence interval, -0.015 to 0.005) in the aspirin group. There was no statistically significant difference between the groups in the annualized rate of change of common carotid intima-media thickness (0.011 mm per year; 95% confidence interval, -0.003 to 0.025). At 12 months of follow-up, 66% of Terutroban patients had no emergent plaques, 31% had 1 to 2 emergent plaques, and 3% had ≥3 emergent plaques. In the aspirin group, the corresponding percentages were 64%, 32%, and 4%. Over time, there was no statistically significant difference in the number of emergent carotid plaques between treatment modalities (rate ratio, 0.91; 95% confidence interval, 0.77-1.07).
CONCLUSIONS: Compared with aspirin, Terutroban did not beneficially affect progression of carotid atherosclerosis among well-treated patients with a history of ischemic stroke or transient ischemic attacks with an internal carotid stenosis <70%.
CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN66157730.
METHODS: A substudy was performed among 1141 participants of the aspirin-controlled Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) trial. Common carotid intima-media thickness and carotid plaque occurrence was measured during a 3-year period.
RESULTS: Baseline characteristics did not differ between Terutroban (n=592) and aspirin (n=549) treated patients and were similar as in the main study. Mean study and treatment duration were similar (28 and 25 months, respectively). In the Terutroban group, the annualized rate of change in common carotid intima-media thickness was 0.006 mm per year (95% confidence interval, -0.004 to 0.016) and -0.005 mm per year (95% confidence interval, -0.015 to 0.005) in the aspirin group. There was no statistically significant difference between the groups in the annualized rate of change of common carotid intima-media thickness (0.011 mm per year; 95% confidence interval, -0.003 to 0.025). At 12 months of follow-up, 66% of Terutroban patients had no emergent plaques, 31% had 1 to 2 emergent plaques, and 3% had ≥3 emergent plaques. In the aspirin group, the corresponding percentages were 64%, 32%, and 4%. Over time, there was no statistically significant difference in the number of emergent carotid plaques between treatment modalities (rate ratio, 0.91; 95% confidence interval, 0.77-1.07).
CONCLUSIONS: Compared with aspirin, Terutroban did not beneficially affect progression of carotid atherosclerosis among well-treated patients with a history of ischemic stroke or transient ischemic attacks with an internal carotid stenosis <70%.
CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN66157730.
Keywords
Aged, Aged, 80 and over, Atherosclerosis/complications, Atherosclerosis/drug therapy, Brain Ischemia/complications, Brain Ischemia/drug therapy, Carotid Artery Diseases/complications, Carotid Artery Diseases/drug therapy, Carotid Artery, Common, Carotid Intima-Media Thickness, Disease Progression, Female, Humans, Male, Middle Aged, Naphthalenes/therapeutic use, Propionates/therapeutic use, Receptors, Thromboxane/therapeutic use, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
10/12/2014 15:24
Last modification date
20/08/2019 15:51
Usage data
